ArticleHematology, transfusion and cell therapy2026
Cost analysis of allogeneic hematopoietic stem cell transplantation before and after the implementation of therapeutic drug monitoring.
Article in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo estimate the costs of allogeneic hematopoietic stem cell transplantation before and after the implementation of therapeutic drug monitoring.
methodsA retrospective cohort study with historical controls included adult and pediatric patients undergoing related, unrelated and haploidentical allogeneic hematopoietic stem cell transplantation from December 2014 to December 2021. The therapeutic drug monitoring (cyclosporine, tacrolimus, and busulfan) group (TDM Group) was compared to a Control Group without therapeutic drug monitoring. A microcosting study based on Time-Driven Activity-based Costing was conducted to assess the hospitalization cost of hematopoietic stem cell transplantation patients. The values of medications and materials were adjusted for inflation to December 2022 and expressed in U.S. dollars
resultsForty-four patients were included in both groups, with data collection from December 2014 to December 2017 (Control Group) and from January 2019 to December 2021 (TDM Group). The average cost per transplantation patient in the entire cohort was US$ 29.604,23 (SD: ± US$ 27.070,00). The hospitalization cost was US$ 32,639.81 (SD ± 31,903.45) for patients in the Control Group and US$ 26,568.65 (SD: ± US$ 21,013.31) for the TDM Group. Regarding the tests performed, the Control Group resulted in a mean cost of US$ 2338.59, with a reduced cost in the TMD Group to US$ 1391.94 (p-value <0.001). The component with the most significant impact on the total cost was medications, with an overall average of US$ 17,728.43 (SD: ± US$ 24,035.77).
conclusionThe total hospitalization cost for allogeneic hematopoietic stem cell transplantation did not differ significantly between groups, but the TDM Group showed lower exam and medication expenditures, suggesting economic benefits. Despite similar overall costs, therapeutic drug monitoring may provide advantages in other clinical outcomes not assessed in this study. Further research is warranted to explore these endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.